The electrophoretic deposition (EPD) is a versatile and cost-effective technique for fabricating advanced coatings. In this study, chitosan/gelatin (CS/G) coatings were prepared on titanium substrates via EPD. The prepared coatings were characterized using fluorescence microscopy, scanning electron microscopy, Fourier transform infrared spectroscopy, X-ray diffraction, and shear bond strength testing. It was found that CS/G coatings had a similar macroporous structure. The gelatin content in the CS/G coatings gradually increased with the increase of the gelatin in the blend solutions. The shear bond strength of the CS/G coatings also increased with the increasing gelatin content. In vitro biological tests demonstrated that human MG63 osteoblast-like cells achieved better affinity on the coatings with higher gelatin content. Therefore, it was concluded that EPD was an effective and efficient technique to prepare CS/G coatings on the titanium surface and that CS/G coatings with higher gelatin content were promising candidates for further loading of functional agents.

A method for electrooxidative C­(sp3)–H amination via intermolecular oxidative C­(sp3)–H/N–H cross-coupling has been developed under metal- and oxidant-free conditions. The C­(sp3)–H bonds adjacent to oxygen, nitrogen, and sulfur atoms could all react smoothly with various amines to give the corresponding products with moderate to good yields (30–93%). In addition, the C­(sp3)–H bonds of benzylic and allylic are also tolerated in this reaction. A preliminary mechanistic study indicates that the C–H cleavage of tetrahydrofuran is probably not involved in the rate-determining step.

This meta-analysis was performed to evaluate the relationship between bruxism and dental implant failure. In contrast to nonbruxers, prostheses in bruxers had a higher failure rate. It suggests that bruxism is a contributing factor of causing the occurrence of dental implant technical/biological complications and plays a role in dental implant failure.

BACKGROUND: Pulmonary arterial hypertension (PAH) is a progressive disease with high rates of morbidity and mortality. Current therapies improve symptoms, functional capacity, and, in select cases, survival. Little is known about patient factors that may predict the likelihood of patient-important, clinically relevant responses to therapy such as the 6-min walk distance (6MWD) and health-related quality of life (HRQoL).